ICLUSIG^® (ponatinib) demonstrated efficacy in patients in 3L or later.

The median time to MCyR in CP-CML patients in the PACE trial was 2.8 months (range: 1.6 to 11.3 months).

Most CP-CML patients who achieved MCyR also achieved CCyR.^*†

*With a minimum follow-up of 48 months, median durations of MCyR had not yet been reached.
^†The primary efficacy endpoint of the PACE trial in CP-CML was MCyR by 12 months.

The PACE trial met its primary efficacy endpoints, with 71% (318/449) of patients
requiring a dose interruption of more than 3 days and 68% (304/449) requiring
a dose reduction.

• The median dose intensity in CP-CML patients was 29 mg/day or 64% of the 45 mg starting dose; median dose intensity was greater in patients with advanced disease.

Efficacy results described should be interpreted within
the context of updated safety information.